INT287127

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 1.63
Pain Relevance 0.67

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Omd) cell adhesion (Omd) proteinaceous extracellular matrix (Omd)
Anatomy Link Frequency
striatum 2
plasma 1
Omd (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Dopamine 75 99.80 Very High Very High Very High
Potency 12 98.42 Very High Very High Very High
Bioavailability 30 98.24 Very High Very High Very High
Catecholamine 21 74.76 Quite High
Central nervous system 12 72.12 Quite High
isoflurane 4 54.76 Quite High
anesthesia 12 54.28 Quite High
depression 1 45.04 Quite Low
Catechol-O-methyltransferase 58 38.72 Quite Low
Hippocampus 16 7.20 Low Low
Disease Link Frequency Relevance Heat
Disease 147 97.36 Very High Very High Very High
Dyskinesias 16 96.16 Very High Very High Very High
Diabetic Retinopathy 1 86.40 High High
Glaucoma 1 85.44 High High
Congenital Anomalies 2 84.72 Quite High
Increased Venous Pressure Under Development 4 82.32 Quite High
Scotoma 3 75.24 Quite High
Decapitation 4 68.80 Quite High
Stress 50 66.40 Quite High
Refractive Errors 1 56.72 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Three of the cases were genetically diagnosed with OMD.
Gene_expression (diagnosed) of OMD
1) Confidence 0.39 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC3010000 Disease Relevance 0.44 Pain Relevance 0
When normal rats (treated with L-DOPA + carbidopa) were given an oral administration of EGCG (at 400 mg/kg), their 3-OMD levels in circulation and striatum were reduced by approximately 30%, clearly reflecting an in vivo inhibition of L-DOPA methylation.
Gene_expression (methylation) of 3-OMD in striatum
2) Confidence 0.03 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2916818 Disease Relevance 0 Pain Relevance 0.07
The observed weaker in vivo potency and efficacy of EGCG in inhibiting L-DOPA methylation (based on inhibition of 3-OMD formation) likely are due to its relatively low oral bioavailability in rats (only approximately 2%) [36], [37].
Gene_expression (formation) of 3-OMD associated with bioavailability and potency
3) Confidence 0.03 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2916818 Disease Relevance 0.25 Pain Relevance 0.31
The exact cause of these adverse effects has not been established at present. 3-OMD, a major metabolite of L-DOPA formed in peripheral and brain tissues, was detected at high levels in the plasma as well as cerebral spinal fluid of PD patients treated with L-DOPA/carbidopa [43], [44], and the plasma levels of 3-OMD in patients with dyskinesia were significantly higher than those from patients without dyskinesia [45].
Gene_expression (detected) of 3-OMD in plasma associated with disease and dyskinesias
4) Confidence 0.03 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2916818 Disease Relevance 0.65 Pain Relevance 0.04
Concentrations of 3-OMD and dopamine in striatum were measured by HPLC with electrochemical detection according to a previously described method [62].
Gene_expression (Concentrations) of 3-OMD in striatum associated with dopamine
5) Confidence 0.03 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2916818 Disease Relevance 0.07 Pain Relevance 0.13
However there are further
               metabolic aspects associated with a decreased 3-OMD synthesis, which is associated
               with homocysteine synthesis.


Gene_expression (synthesis) of 3-OMD
6) Confidence 0.01 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778405 Disease Relevance 0.22 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox